These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 22781292)

  • 1. [Combination of recombinant human endostatin and neoadjuvant chemotherapy for breast cancer].
    Chen JH; Li D; Yao Q; Zhang JL; Wang T; Wang L
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(10):668-71. PubMed ID: 22781292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
    Chen J; Yao Q; Li D; Zhang J; Wang T; Yu M; Zhou X; Huan Y; Wang J; Wang L
    BMC Cancer; 2013 May; 13():248. PubMed ID: 23693018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01).
    Chen J; Yao Q; Huang M; Wang B; Zhang J; Wang T; Ming Y; Zhou X; Jia Q; Huan Y; Wang J; Wang L
    Int J Cancer; 2018 May; 142(10):2130-2138. PubMed ID: 29238974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
    Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
    Jia Q; Xu J; Jiang W; Zheng M; Wei M; Chen J; Wang L; Huan Y
    Int J Med Sci; 2013; 10(2):110-8. PubMed ID: 23329881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
    Mohammadianpanah M; Ashouri Y; Hoseini S; Amadloo N; Talei A; Tahmasebi S; Nasrolahi H; Mosalaei A; Omidvari S; Ansari M; Mosleh-Shirazi MA
    Breast Cancer Res Treat; 2012 Apr; 132(3):853-61. PubMed ID: 22002564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
    Lu S; Li L; Luo Y; Zhang L; Wu G; Chen Z; Huang C; Guo S; Zhang Y; Song X; Yu Y; Zhou C; Li W; Liao M; Li B; Xu L; Chen P; Hu C; Hu C
    J Thorac Oncol; 2015 Jan; 10(1):206-11. PubMed ID: 25654728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].
    Wang J; Sun Y; Liu Y; Yu Q; Zhang Y; Li K; Zhu Y; Zhou Q; Hou M; Guan Z; Li W; Zhuang W; Wang D; Liang H; Qin F; Lu H; Liu X; Sun H; Zhang Y; Wang J; Luo S; Yang R; Tu Y; Wang X; Song S; Zhou J; You L; Wang J; Yao C
    Zhongguo Fei Ai Za Zhi; 2005 Aug; 8(4):283-90. PubMed ID: 21108883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
    Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Parallel Controlled Phase II Trial of Recombinant Human Endostatin Added to Neoadjuvant Chemotherapy for Stage III Breast Cancer.
    Zhang X; Zhang Z; Cao M; Liu B; Mori M; Luoh SW; Bergan R; Liu Y; Liu Y
    Clin Breast Cancer; 2020 Aug; 20(4):291-299.e3. PubMed ID: 32482525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
    Costa SD; Loibl S; Kaufmann M; Zahm DM; Hilfrich J; Huober J; Eidtmann H; du Bois A; Blohmer JU; Ataseven B; Weiss E; Tesch H; Gerber B; Baumann KH; Thomssen C; Breitbach GP; Ibishi S; Jackisch C; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Jan; 28(1):83-91. PubMed ID: 19901111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
    Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
    Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of the cardiotoxicity of recombinant human endostatin using myocardial biochemical markers in cancer patients].
    Qin J; Zhang PH; Qian XY; Kang SJ; Luo RC; Wang YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):930-2. PubMed ID: 18583230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer.
    Wenzel C; Locker GJ; Pluschnig U; Zielinski CC; Rudas M; Oberhuber G; Gnant MF; Taucher S; Jakesz R; Steger GG
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):155-9. PubMed ID: 12172982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant chemotherapy for primary breast cancer].
    Li JF; Ouyang T; Wang TF; Lin BY
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer.
    Zhang J; Chen RX; Zhang J; Cai J; Meng H; Wu GC; Zhang ZT; Wang Y; Wang KL
    Chin Med J (Engl); 2012 Jun; 125(12):2144-50. PubMed ID: 22884144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
    Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
    Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.